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ABSTRACT. The impact of formulation variables on aerodynamic and electrostatic properties of dry
powder aerosol particles is of great importance to the development of efficient and reproducible inhaler
products. Systematic evaluation requires a well-designed series of experiments using appropriate methods.
A factorial experimental design was employed. In broad terms, the conditions considered were two drugs,
albuterol and budesonide, in combination with different excipients, drug concentrations, delivered doses,
and metering system (capsule composition) and sampled under different flow conditions using standard
entrainment tubes. Samples were collected in an electrical low-pressure impactor, to evaluate distribution
of electrostatic properties, and an Andersen eight-stage nonviable cascade impactor, to estimate aerody-
namic particle size distribution, concurrently. The deposition studies allowed calculation of approximate
per particle charge levels for drug. The results showed very high particle charge levels, often in the 1,000–
10,000 of elementary charges per particle range, orders of magnitude higher than charge levels predicted
by the Boltzmann charge distribution. The charge levels are considerably higher than had previously been
estimated (200e per particle).
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INTRODUCTION
Dry powder inhaler (DPI) formulations and devices have
characteristics that can give rise to surface charging or
triboelectrification. When the patient actuates a DPI, the
formulation is fluidized and dispersed; drug and carrier parti-
cles separate from each other. Charges can be transferred
during this process resulting in net particle charges, which
may affect particle trajectory and deposition. Particles experi-
ence significant friction during DPI discharge, which tends to
amplify these effects.
Aerodynamic and electrical property experiments may be
performed to elucidate these properties with respect to the
aerosol behavior of the formulation. Using the electrical low-
pressure impactor (ELPI), the experimental apparatus per-
mits the simultaneous determination of particle size and
charge distribution of the fine particle fraction of the emitted
aerosol, which are important prerequisites for understanding
formulation behavior.
The ELPITM
The experimental apparatus relies on the ELPITM
(Dekati Ltd, Tampere, Finland), an aerodynamic particle
sizer that detects particles by charge (1,2). The ELPI has
primarily been used in the automotive industry (2–5) and in
industrial hygiene applications (6,7). More recently, it has
been applied to the evaluation of electrostatic phenomena in
medicinal aerosols, including metered dose inhalers (MDIs)
(8) and DPIs (9).
A detailed discussion of the ELPI is available elsewhere
(10). Briefly, the ELPI is composed of a low-pressure cascade
impactor and a unipolar corona aerosol charger that charges
the incoming aerosol uniformly prior to entry into the cascade
impactor. Operating at a reduced pressure (10 kPa on the final
stage), the ELPI collects particles down to a size of 30 nm, the
cutoff diameter of the bottom stage (stage 1). The cutoff
diameters of the other 12 stages are 10.2, 6.56, 4.09, 2.52,
1.66, 1.02, 0.66, 0.41, 0.27, 0.17, 0.11, and 0.06 μm, respectively.
As is the case in other impactors, deposition inside the ELPI
depends on particle aerodynamic diameter. But unlike con-
ventional cascade impactors, which are disassembled after
operation for chemical or gravimetrical assay of the stages,
an ELPI detects particle deposition by measuring the current
resulting from dissipation of the particles’ electrical charges.
The collected particles can be measured simultaneously on all
stages using a multichannel electrometer and are reported in
real-time on a computer. Thus, when operated with charger
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turned on, the ELPI functions as a real-time particle sizer; this
is the standard ELPI configuration.
The ELPI can also be operated with the charger turned
off. In this configuration, the incoming aerosol is not charged
within the ELPI and the electrometer measures only native
particle charges. Since each impactor stage is electrically iso-
lated from the next, charges can be measured across individual
stages, allowing the evaluation of size-specific charging with
accurate determination of charge magnitude and polarity on
particles in the respirable size range over time.
Background
Studies of medicinal aerosol electrostatics have been
attempted before. Electrostatic charge carried by a DPI aero-
sol cloud has been measured using a grid probe (11); however,
the particles were rather large and the system was of little
pharmaceutical relevance. The effects of particle morphology
and crystallinity on triboelectrification of DPIs have also been
studied, but particle deposition was not considered (12).
Moreover, the studies relied solely on Faraday cage charge
measurements, which precluded analysis of fine particle sizes
and size-dependent charge distribution.
A preliminary analysis of DPI electrostatics in a pharma-
ceutically relevant system was previously published by the
authors (9); these studies provide the foundation for the work
described here and can be summarized as follows:
1. An experimental apparatus was developed that
allowed inhalers to be tested at an airflow rate of
60 L/min, as recommended by the FDA and US Phar-
macopeia (13), and the electrical charge of the respi-
rable fraction to be determined. The same setup is
used in the present work.
2. Initial experiments assessed the ability of the ELPI to
classify therapeutic aerosols consistently and in accord
with a conventional inertial impactor, i.e., the Ander-
sen eight-stage nonviable impactor. ELPI particle size
distributions were in agreement with those determined
from ACI deposition measurements.
3. The particle size distributions acquired by ELPI were
compared to those obtained from gravimetric analysis
of the stages; agreement was good with almost super-
imposable particle size distributions and same d25, d50,
and d75 values. The ELPI system proved more precise
and reproducible in the lower particle size ranges.
4. Deposited particle charge was shown to vary signifi-
cantly between different particle size fractions of a
given formulation as well as between formulations.
5. The study revealed that pharmaceutical product prop-
erties such as excipient, inhaler type, and metering
system significantly affect the extent to which formu-
lations experience triboelectrification. Both charge
magnitude and polarity were affected consistently.
These experiments constituted the most comprehensive
study of DPI triboelectrification phenomena at the time. They
demonstrated that triboelectrification is a significant phenom-
enon in DPI actuation. Yet, the study had several shortcom-
ings that the present study addresses. Charging effects are
confounded by particle size distribution and mass depositions
since the stages of the ELPI were not assayed for drug and
excipient deposition during individual actuations. Moreover,
excipients contained sizeable proportions of fine particles that
were deposited together with the micron-sized drug after for-
mulation actuation. As a result, it is unclear which material
contributed to charge on each stage; tribocharging could not
be conclusively linked with fine particulate drug, and the
magnitude of particle charge could not be established. How-
ever, this information is needed to determine whether parti-
cles carry sufficient charge to affect delivery.
EXPERIMENTAL DESIGN
The goal of the experiments was to elucidate the phenom-
enon of electrostatic charging in a DPI by simultaneously study-
ing charge and mass deposition following DPI actuation.
Establishing which formulation variables contribute to charging
has consequences for product development. However, the num-
ber of possible variables to study in this context was potentially
large. The choice of a discriminating experimental design with
appropriate input factors and responses was critical.
Design Factors
Drugs: Albuterol Sulfate, Budesonide
Albuterol (USAN) or salbutamol (INN) is a short-acting β2-
adrenergic receptor agonist used for the relief of bronchospasms
in asthma and chronic obstructive pulmonary disease (COPD).
Albuterol (molecular weight (MW) 239.3) is a commonly inhaled
medicine and frequently used as a model drug in medicinal
aerosol research.
Budesonide (MW 430.5) is a glucocorticoid steroid for
the treatment of asthma, noninfectious rhinitis, and allergies.
Budesonide is marketed as Pulmicort® with a Turbohaler DPI
by AstraZenaca (14). It was selected because it is a different
therapeutic category of drug and is structurally very distinct
from albuterol.
Excipients: Lactose Monohydrate, Glucose, Calcium
Phosphate (CP)
Lactose is the most common excipient in DPI formula-
tions. It was the only excipient used in the preliminary exper-
iments and is the primary excipient in the formulations tested
in this study. In addition to lactose, glucose was tested. It has
previously been employed in DPI formulations (15) and is
thus a relevant substance to compare. CP was chosen for study
because it is a chemically different material (inorganic salt),
which offers a contrast to the sugars usually employed. While
it is a physiological salt that is widely used in the formulation
of oral dosage forms, it has not been used in DPI formulations.
Excipient Sieve Fractions: 45–75, 75–105, and 105–150 μm
Three sieve fractions were selected because they were
size ranges available for most excipients (all but the sieved
lactose batches, where all particles are smaller than 75 μm). A
lower limit of 45 μm was selected to allow the most complete
removal of excipient fines, which might otherwise be deposit-
ed on the stages of the ELPI, confounding the analysis.
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Excipient Batch-to-Batch Variability (Lactose Only): Two
Milled (ML), Two Sieved (SV) Lactose Products
Since batch-to-batch variability is a well-known problem,
several lactose products and batches were used to make for-
mulations. Sieved lactose batches (SV) have undergone siev-
ing as the only process step after crystallization while milled
batches (ML) have been milled after crystallization at the
manufacture site.
Drug Concentration: 0.25%, 0.50%, and 1.0%
DPI formulations are interactive powder blends contain-
ing low drug concentrations, often at the 0.5–2% mass/mass
range. These concentrations ensure that drug particles remain
separated from one another and, thus, maintain their primary
particle size, i.e., they do not aggregate significantly. Drug
concentrations are an important determinant of drug/carrier
particle interactions. The drug concentration was examined at
three levels to evaluate particle separation and charging. Car-
rier particle surfaces are heterogeneous with a number of
particularly energetic “active sites” (16); using different drug
concentrations, these active sites may be probed. The pres-
ence of active sites would likely be manifested in particle
association resulting in deposition differences that are nonlin-
ear with respect to drug concentration. The reason for having
a very low concentration, 0.25% loading, of drug in the exper-
imental design is that particles are likely to be in closer contact
with the more highly energetic active surface sites.
Dose: 10, 20, 30, and 40 mg
The dose range is relevant to DPI formulations. Nonlin-
ear responses of charging and drug deposition to changes in
dose may elucidate the fluidization and charging pattern.
Fluidization Conditions: Standard Entrainment Tubes
Preliminary studies were conducted using two different
inhaler devices, the Rotahaler® (GlaxoSmithKline, RTP, NC)
and the Inhalator® (Boehringer Ingelheim, Germany) single
capsule inhaler, a low-pressure drop and a high-pressure drop
device, respectively (17). Study results indicated a strong cor-
relation between choice of inhaler and both magnitude and
polarity of acquired charge. However, this correlation could
not be firmly linked to a change in pressure drop or device
resistivity because the devices also differed in material and
operational principles, which confounded comparisons be-
tween the devices. To eliminate this source of variability,
standardized entrainment tubes (SETs) replaced DPI devices
as aerosol dispersion systems. SETs are simple steel tubes of
specific dimensions in which well-characterized airflow pat-
terns are established (18).
Product Batch-to-Batch Variability (Variability in Manufacture)
Manufacture of select batches was repeated to determine
if the observed phenomena were the result of fundamental
material properties (as postulated) rather than the result of
environmental or random effects that might arise during
manufacture.
Study Design
The mere combination of excipient, batch, and sieve
fractions results in 14 different excipient building blocks. If
each of these were to be tested at two levels, the total number
of individual formulations would be 14×2 (drugs)×2 (conc)=
56 formulations. Testing at 2 doses and 2 fluidization condi-
tions would require 224 experiments, which does not account
for the allocation of replicates (to test reproducibility and
manufacture consistency). If all levels discussed above were
tested, the study would require 14×2×3×4×3×4×3=12,096
experiments (again excluding allocations for reproducibility
and manufacture consistency). Efficient experimental alloca-
tion is crucially important.
In determining the appropriate statistical design, several
competing objectives were weighed. Picking a standard design
scheme, such as a fractional factorial or central composite
design is attractive because it provides the ability to
interpret all generated data simultaneously using well-
established statistical tools and generate response surfaces
that may allow interpolation and extrapolation. However,
given the large number of factors (in particular, categorical
factors such as the 14 different excipient building blocks), this
design would be difficult to construct and in the end would still
require sufficient trials to be impractical. Consequently, a
different approach was required.
The experimental design developed was a series of exper-
iments in a design framework rather than a purely statistical
design scheme. While it contains elements of both half and full-
factorial designs, it was structured to test specific (if conditional)
hypotheses rather than to determine a multidimensional re-
sponse surface. Using this experimental framework, the results
cannot be interpreted generally butmust be considered discrete-
ly. Specific hypotheses, represented by the design factors listed
in Section 2.1, were tested using a two-level design with a
number of intermittent or extreme points at various positions
to gauge the response surface curvature where it appeared to
play a role. The design, which is shown schematically in Fig. 1, is
based on the assumption that most factors are independent and
that marginal effects are more important than interaction ef-
fects. In all, the design required 33 formulations to be tested in
63 experiments, which provided sufficient time for the repetition
of a sizable portion of experiments, thereby increasing statistical
power. In Fig. 1, each circle denotes an experiment, for which
three sets of electrical charge data and one set of mass deposi-
tion data were determined.
The design is built around a central set of experiments
that compares each excipient in a standard formulation (0.5%
albuterol in 45–75 μm sieve fraction of excipient) to the other
five excipients using a common set of actuation conditions
(40 mg, SETA). There are two full-factorial experimental sets
using the two milled lactose batches (ML80 and ML58) aimed
at gauging the effects of drug concentration (0.5% and 1.0%),
fluidization conditions (SET A vs. SET C), dose (20 mg vs.
40 mg), and half-factorial designs for each of the other excip-
ients. The purpose of collecting two full-factorial sets for
ML80 and ML58 is that the differences between the batches
are assumed to be minute (batch-to-batch variability), much
smaller than the differences expected between the different
materials. A full-factorial design has greater potential to dis-
criminate differences. Using ML80 only, the effects of drug
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concentration (0.25% albuterol), fluidization conditions (SET
D), and dose (10 mg, 30 mg) were further investigated. These
experiments were to provide insight on the response surface
curvature with respect to these variables. The central design
(triangular prism) with a full-factorial assessment aroundML80
is repeated for budesonide; this should allow a comprehensive
comparison of drug identity for each excipient, as well as con-
founded effects (interactions between drug, drug concentration,
fluidization conditions, and dose) for ML80 lactose formula-
tions. Finally, the cube on the left provides comparisons of the
different sieve fractions for each of the four excipients for which
the larger sieve fractions are obtainable, that is, the two milled
lactose batches (ML80, ML58), glucose, and CP. Once again,
using ML80 lactose, the confounding effects of sieve fraction
and drug concentration may be examined. While this is one of
the aforementioned conditional tests, if an effect is observed, it
may well exist for some of the other excipients.
Of the 63 experiments that were conducted in this frame-
work, 28 involve ML80 lactose (12 out of 33 formulations).
Thus, a very thorough study of ML80 lactose behavior is
obtained, allowing a complete examination of all possible
interactions of the different variables. Examinations of the
other excipients are less comprehensive.
To ensure that formulations would be tested within a
week after manufacture, the order of the formulations was
randomized first, and then the different actuations were ran-
domized within blocks of ~5 formulations. Formulations were
then manufactured. This ensured that formulations were not
subject to different storage effects.
To evaluate the reproducibility and possible storage effects,
20 of the 63 experiments were randomly selected for retesting;
several of these would be retested several times after varying
periods of storage. To evaluate the variability associated with
the manufacture, seven formulations were randomly selected
for remanufacture and were subsequently retested using the
same experimental conditions and settings. In addition, several
formulations were selected to check the effect of environmental
conditions, including the effect of high relative humidity (RH)




Lactose monohydrate, Respitose™, was provided by
DMV-Fonterra Excipients (Goch, Germany). Two batches of
milled (ML001, batches 10136780 and 10138058) and two
batches of sieved (SV003, batches 10190094 and 10135425)
lactose were evaluated. (For convenience, the batches will be
referred to as ML80, ML58, SV94, and SV425, respectively.)
Dextrose (D-glucose), LycadexTM, was provided by Roquette
(Keokuk, IA). Calcium phosphate, A-TabTM, was obtained
from Innophos (Cranbury, NJ). To control for differences in
particle size in the experiments, all excipient batches were
sieved prior to use in the formulations and experiments.
Fig. 1. Experimental framework developed to study the electrostatic effects of the variables. Each circle
denotes a different experimental setting. The framework contains elements of factorial and central compos-
ite design but was developed to test specific hypotheses. The main elements of the design are denoted by red
boxes. The design is described in detail in the text
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Drugs
Milled albuterol sulfate (median particle size 2 μm) was
obtained from Chemaco (Beetsterzwaag, NL) from drug
manufactured by P.F.C. Italiana S.r.1 (Caronno Pertusella,
Italy). Budesonide was obtained from Sigma-Aldrich (St. Lou-
is, MO) and was jet-milled to a single-micron size range,
verified using laser light scattering.
Dispersion Devices
To understand the effects of fluid dynamics on
triboelectrification, three SET were used, giving low, interme-
diate, and high specific resistance values of 0.021, 0.046, and
0.140 cm H2O
0.5/(L/min), respectively (18). The relevant
properties of these SETs in comparison with the two
previously tested devices are shown in Table I; SETs A, C,
and D provide high, low, and very low resistivity devices,
likely to provide evidence of a range of performance of the
formulations in response to airflow conditions. These devices
have been used previously in a series of studies intended to
correlate particle dispersion with shear conditions (19–24).
Methods
ELPI Experimental Apparatus
The experimental apparatus was developed during prelim-
inary studies to overcome two major obstacles, (1) operation at
30 L/min and (2) pre-separation of large agglomerates (of no
therapeutic importance). (1) The ELPI operates at 30 L/min,
but DPIs are typically tested at 60 L/min airflow rates which
more closely approximates the inspiratory airflow rate; (2) un-
like the ACI (ThermoAndersen, Smyrna, GA), the ELPI does
not have a pre-separator capable of removing large quantities of
coarse material. However, initial trials made clear that failure to
remove carrier particles and agglomerates from the aerosol
prior to introduction into the ELPI could result in flooding the
top stages after a single inhaler actuation. The setup that was
devised to address these issues is shown in Fig. 2. This approach
allows a flow rate of 60 L/min at the site of actuation, segregation
of coarse material, and dispersion and deposition of airborne
particles in two parallel collection devices, the ELPI and ACI,
each operated at 30 L/min. A SET is connected to the standard
USP induction throat, which is connected to the ACI pre-sepa-
rator (loaded with 15 mL water or methanol) (cutoff size of
8.6 μm at 60 L/min). A custom-manufactured aluminum
connector from the pre-separator split the 60-L/min
stream in two equal streams; 40 cm TygonTM tubing
(R3603) was used to connect the two outlets with ELPI
and ACI, each employing a vacuum pump operating at
30 L/min. Tygon tubing is commonly used in aerosol research
because, unlike other materials, Tygon has negligible electrostatic
effects (25). Deposition of drug in different parts of the
experimental apparatus was determined in preliminary studies;
deposition in the custom-made part and tubing accounted for
<5% of deposition in the ELPI and ACI. To prevent particle
bounce, ACI collection plates were coated with silicone oil.
Coated aluminum foils were used with the ELPI stages. The
apparatus was leak tested prior to each experiment. In
accordance with manufacturer recommendations, the ELPI was
switched on at least 1 h prior to measurement. Inlet air was not
filtered and baseline measurements of charge were collected.
Actuations
Formulations were weighed on an analytical balance,
dispensed onto weighing paper and placed in front of the
entrainment tube for actuation into the experimental appa-
ratus. Preliminary studies indicated that three actuations
were required to ensure sufficient material was deposited
on all ELPI stages. To determine the charge contribution
of excipient only, for each experimental setting, the three
formulation actuations were preceded by three actuations
of excipient only. In sequence, for each setting, the appa-
ratus was turned on, the electrometer channels were zero-
ed, and, once the signal stabilized, the actuations proceeded
in the order: placebo; active formulation; placebo; active
formulation; placebo; and active formulation. All active
and placebo formulations were weighed out prior to the
experiment and approximately 10 s was allowed between
actuations. Electrical charge across 12 stages during actua-
tions was recorded using the ELPI V acquisition software.
Analysis of Drug Deposition on ELPI Stages
After each set of three actuations for a given formulation,
the ELPI was turned off and the apparatus was disassembled
and washed. The coated aluminum foils were removed from
the ELPI stages and washed with 3 mL water (albuterol
formulations) or 3 mL methanol (budesonide formulations).
CP formulations (limited aqueous and methanol solubility)
were centrifuged to separate any undissolved excipient. UV
absorbance of the supernatant solutions was assessed at a





ΔP Power Shear stress
cm H2O
0.5/(L/min) (N/m2) (W) (N/m2)
A 0.140 18,440 6,920 6.92 13.14
C 0.046 11,070 747 0.747 2.20
D 0.021 7,720 156 0.156 0.62
Rotahaler 0.040 N/A
Inhalator 0.180 N/A
SET standardized entrainment tube, N/A not available
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wavelength of 224.5 nm (albuterol) or 244 nm (budesonide)
using a Shimadzu 160U spectrophotometer. The excipients
have negligible absorbance at this wavelength.
Environmental Conditions
Triboelectrification is only observed at relative humidities
of less than 65% (26). Hence, conditions must be monitored.
The experiments were performed in the climate-controlled
laboratory over the course of several months; the conditions
during blending, storage, and actuation were constant at a
temperature of 23±0.5°C and a relative humidity of 35±5%.
Environmental Effects Study
When a patient actuates an inhaler and the drug particles
enter the airways, they are entering a high humidity (100%RH)
environment. High RH is known to inhibit triboelectrification.
However, it is unclear if the environmental conditions in the
airways, to which drug particles are briefly exposed, can also
dissipate the particles’ charges. This was determined using a
modified apparatus, which is similar to Fig. 2 with an ultrasonic
humidifier (Vicks V-5100, Procter & Gamble, Cincinnati, OH)
generating water vapor immediately next to the SET inlet, so
that humid air instead of ambient air is drawn into the
apparatus.
Surface Effects Study
Triboelectrification is a surface effect; different surfaces
interact with materials and result in specific charging behavior.
It is important to understand the choice of surface from which
the formulation is actuated. Two formulations were actuated
into the experimental apparatus from a series of different
surfaces, including weighing paper, polyethylene (PE)
weighing dish, aluminum weighing dish, a gelatin capsule,
and carageenan capsule. Only the ELPI charge deposition
data was recorded for these and was subsequently compared.
Data Analysis
Charge data were collected by the ELPI data acquisi-
tion software (ELPIVI 4.0, Dekati, Tampere, Finland).
Raw data were transferred to and analyzed in Excel
(Microsoft, Seattle, WA). Each actuation was isolated and
charge was integrated over the time the actuation had
occurred. Since there were three actuations of active for-
mulation for each experiment, the charges were averaged
and standard deviations determined. Drug deposition was
determined from chemical assay of the ELPI stages and
plotted in Excel.
The set of 63 experiments provides a large dataset. How-
ever, the data represents a custom design; containing elements
of factorial and central composite design. Data were trans-
ferred to statistical software SPSS 16.0 for Windows (SPSS
Inc., Chicago, IL) and analyzed using the general linear model
multivariate analysis feature. The response elements exam-
ined included d25, d50, d75, fine particle fraction, as well as
total charge magnitude and polarity (summed across all
stages), absolute magnitude of the charges recovered, and
charges recovered on stages 1–3, 4–6, 7–9, and 10–12. Another
response variable tested was charge/fine particle mass. As-
suming the particles were perfect spheres of a uniform size
at the midpoint between two stages, the average particle
charge was determined and adapted as a response variable.
All of the response variables were examined with respect to
each of the formulation factors in a series of statistical tests.
Fig. 2. Experimental apparatus for parallel sampling by ELPI and ACI (adapted from
Telko et al.(9))
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RESULTS AND DISCUSSION
Reproducibility of ELPI Experiments
Preliminary experiments had shown good reproducibility
of charge distribution profiles for a given formulation performed
at constant conditions (9). This consistency was also observed in
the current trials, as is highlighted in Fig. 3. Twentymilligrams of
1% albuterol in ML58 lactose, 45–75 μm sieve fraction, was
actuated from SET A three times (separated by actuations of
placebo formulation); the procedure was repeated 9 days later.
As is evident in Fig. 3, the actuations were consistent within a
given day and consistent over the course of several days. Differ-
ences in magnitude of up to 20% were common, but charge
polarity and rank/order of the stages was retained in all trials
(compared to other formulations and/or conditions).
Storage times of less than 2 weeks generally resulted in
highly reproducible charge and particle size distributions with
variability similar in magnitude to intra-experimental variabil-
ity observed when experiments were performed in sequence
(on the same day). In Fig. 4, a formulation was retested 5 days
after the original sample was examined; this formulation
(0.5% albuterol in 45–75 μmML80 lactose) showed very good
reproducibility in both mass-deposited (fine particle mass
(FPM) and fine particle fraction (FPF)) and charge distribu-
tions (integrated rather than stage specific as in Fig. 4).
Variability in mass and charge deposition profiles in-
creased after more than 2 weeks of storage (at ambient con-
ditions). In many cases, the differences observed after storage
were so dramatic that the replicates were no longer represen-
tative of the original system. In other words, many of the
formulations were subject to significant storage effects. As a
result of these effects, all replicates subject to storage effects,
i.e., those with storage times exceeding 2 weeks, were exclud-
ed from the experimental analysis.
Remanufactured Product Variability and Storage Effects
Another aspect of variability is that associated with manu-
facture. While the same process of manufacture is applied to all
formulations, themajor processing step of blending is by its nature
a random process. If the variability associated with the product
manufacture results in significant differences in formulation be-
havior, variability from other factors would be difficult to discern.
In light of the observations made with respect to storage, under-
standing the variability of the manufacture process is essential.
Figure 5 shows the mass and charge deposition profiles
for a formulation (0.5% albuterol, ML58 lactose, 75–106 μm
sieve fraction) manufactured twice. Both mass and charge
deposition profiles are almost superimposable, indicating a
high level of reproducibility.
Figure 6 compares two batches of product, one actuated
soon after manufacture (blue) as well as after 36 days of
storage (red) and a remanufactured formulation actuated
2 days after manufacture (green). Clearly, the remanufactured
formulation is more similar to the original formulation than to
the formulation that has undergone storage. This suggests that
the variability in the process is not significant but that the
storage effects are significant. The large magnitude of the
storage effect was an unanticipated and warrants closer inves-
tigation. However, pursuit of this objective is outside the scope
of the present discussion of electrostatics.
Fig. 3. Six actuations of 1% albuterol in ML58 lactose, 45–75 μm sieve fraction, and 20 mg
actuated from SETA. The first three were performed on 1 day separated only by actuations
of excipient, the next three performed 9 days later, also separated by excipient actuations
(excipient actuations have been removed from this graph). Double line indicates temporal
discontinuity. In each case, deposition on stages is complete in about 6 s. While there is
some variability with regards to magnitude, the overall rank/order and polarity is highly
preserved in each trial
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Two formulations were actuated into the experimental
apparatus from a series of different surfaces, including
weighing paper, a PE weighing dish, a gelatin capsule, and a
carageenan capsule. Figure 7 shows the results of one of these
experiments, charge depositions over time for a formulation of
1% albuterol in ML58 lactose, 45–75 μm sieve fraction, and
20 mg actuated from SET A; the formulation had been dis-
pensed onto each of the different surfaces and had been kept
there for at least 30 min prior to actuation. The choice of
surface did not appear to have a significant effect on the
charging properties of the FPF within the ELPI in either case;
the charging recorded on the individual stages follows the
same pattern in each case, and the differences in overall
magnitude were in the order of inter-actuation variability.
These observations are important because it shows that
the electrical charges are the result of tribocharging, i.e.,
charge transfers between the particles of the formulation.
These charges are the result of electron transfer during parti-
cle contact during and after the blending process; the charges
are exposed when the particles are separated from one
another during the actuation process. This point in particular
can be deduced from the fourth actuation shown, in which the
blend was actuated from weigh paper after it had been treated
with Zerostat® antistatic gun, which removes static charges by
releasing a stream of bipolar ions. This treatment ensures that
the system as a whole is uncharged. The charges, shown in
Fig. 7, were integrated over time and summed across the
stages; the results of this are shown in Table II. Differences
in charge (simple sum and sum of absolute magnitude) are
within the normal variability.
As shown in Fig. 8 and Table III, another formulation
containing budesonide in sieved lactose displayed the
same behavior, i.e., charge distribution was independent
of the surface of last contact, even as the actual charging
was very different from the previous formulation. In this
case, highly negative charges were recorded for all actua-
tions, suggesting that the milled budesonide had a higher
pseudo-work function than the sieved lactose leaving its
particles with an excess of electrons after separation from
the sieved lactose.
Fig. 4. Formulation (0.5% albuterol in 45–75 μm ML80 lactose, 40 mg) actuated from SETA (three times)
on different days, separated by 5 days of storage. The differences in deposition (actual quantities shown) are
minimal. Differences in charge distribution mirror the differences in deposition and are within a standard
deviation from one another
Fig. 5. Remade formulation (0.5% albuterol in 75–106 μm ML58 lactose) actuated from SET A (three
times)
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Environmental Effects
When drug particles enter the airways during inhaler
actuation, they are entering a high humidity environment.
Although high RH can inhibit triboelectrification, it is unclear
if brief exposure is sufficient to dissipate particle charges. To
determine the effect of high RH during aerosol transport, an
ultrasonic humidifier was operated adjacent to the SET inlet,
so that humid air was drawn into the apparatus. Actuations of
1% albuterol in ML58 lactose, 45–75 μm sieve fraction, and
20 mg actuated from SETA (same as Fig. 8) were performed.
The charges recorded on the stages of the ELPI are shown in
Fig. 9. The first two peaks show previous experiments per-
formed at ambient humidity (35% RH), and the next three
were performed at high humidity (95% RH). Then, the hu-
midifier was turned off and another two actuations were per-
formed at ambient humidity. While the high humidity greatly
increases the noise on the stages, the actuations are essentially
unchanged. Charge distribution and magnitude are the same
as in a low humidity environment. This confirms that charging
is a relevant phenomenon during clinical DPI use. Whether
there is sufficient triboelectrification to affect particle trajec-
tory and deposition was determined in later experiments.
Experimental Design Analysis: Effect of Formulation Factors
on FPM and Particle Size Distribution
To understand how particle charge is affected by formu-
lation and actuation factors, the charge levels need to be
considered relative to the mass of the deposited aerosol par-
ticles. In the current project, charge distributions were record-
ed using the ELPI, then the mass deposition on each stage was
determined by chemical assay. (Since the single depositions
were close to the limit of detection on some stages, mass was
assayed for a pooled set of three subsequent depositions of the
same formulation and averaged.) As a result, we can discern
how the formulation variables affect drug deposition and ap-
ply the results to the analysis of charging.
After each actuation experiment, the ELPI was
disassembled and the stages assayed. The mass on each indi-
vidual ELPI stage was determined, total deposited mass and
FPF were calculated, and particle size distributions (PSDs)
were generated. These measures are used in conjunction with
the charging data, but it is also instructive to consider them
individually, since they present a rich dataset of formulation
effects on PSD. The PSDs are first discussed qualitatively,
then in context of the statistical analysis.
Statistical Analysis: General
For the experimental design analysis, the PSD data were
reduced to a smaller number of descriptive parameters
Fig. 6. Same formulation (0.5% budesonide in 45–75 μm SV425 lactose) actuated from SETA (three times)
on different days, separated by 36 days of storage. Also shown remade formulation, actuated day after it was
made. The remade formulation has FPF similar to the old formulation without storage, while storage results
in higher deposition. Charge deposition profiles are similar for all
Fig. 7. Albuterol (1%) in ML58 lactose, 45–75 μm sieve fraction, and
20 mg actuated from SETA, off different surfaces. The eight actuations
were performed in a row with intermittent placebo actuations. There are
minor magnitude differences but the charge deposition profiles are
largely the same. This supports the hypothesis that the charges observed
are the result of triboelectrification during actuation, when particles have
undergone charge transfer and those charges are exposed
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consisting of d25, d50, d75 (determined by linear interpolation
of the particle size distribution data), and FPF, which were
evaluated by multivariate statistics.
Since the drugs have different primary particle sizes, an
evaluation of the entire dataset showed very strong codepen-
dency of the results on the identity of the drugs. This is expected.
As a result, all significant effects contained the drug as a cofac-
tor. To overcome this problem, the datasets for the two drugs
were analyzed separately. The results of this analysis are sum-
marized in Table V (budesonide) and Table V (albuterol).
Table V summarizes the significant effects of the formu-
lation variables on the particle size and mass distribution of
budesonide actuated from different formulations. The table
follows the same format and gives the same kind of informa-
tion as the subsequent result tables.
The first two rows in the table describe the data in terms
of the mean (±standard deviation) and the range for the entire
dataset. Subsequent rows show the results of the statistical
analysis. The statistical analysis was conducted in SPSS using
the general linear model (GLM) multivariate procedure. The
procedure provides regression analysis and analysis of vari-
ance (ANOVA) for the dependent variables (i.e., d25, d50, d75,
and FPF) by factor variables (i.e., excipient, drug conc., fluid-
ization conditions). The effects of factor variables on the
means of dependent variable groupings were tested, and the
interactions between factors and the effects of individual fac-
tors were probed. Only the effects of individual factors are
reported in Table V and subsequent result tables because
these are general and apply to different systems. The tables
also provide effect size estimates based on the unbalanced
full-factorial model (unbalanced because, as described above,
certain factor combinations were not tested). The effect size
describes the proportion of total variability attributable to a
given factor. The confidence interval for each test is also given;
the significance level was set to α=0.05, and only effects with
lower p values are reported. For each category of factor
(underlined), the cells to the right indicate whether the effect
on the given response was significant. Where the effects are
statistically significant, the p value is indicated and the rows
below give the individual factor contribution (parameter) es-
timates; again, where these contributions are significantly dif-
ferent from the other variables of the category, the p value is
indicated. One of the variables serves as a basis of comparison
in each case and is assigned a contribution of 0; the effects of
the other variables are given relative to it. The basis of com-
parison is SV94 lactose, 45–75 μm sieve fraction, 1.0% drug
concentration, and the highly turbulent actuation conditions
(SETA, Re=18,440). The model intercept is also given in the
tables. This intercept provides the default response value in
absence of the factor effects. Thus, to highlight an example
from Table V, the d25 of budesonide after release from a
0.25% drug in ML80 formulation, actuated at Re=18,440, is
expected to be 0.96–0.16+0.28+0.00=1.08 μm; this result is
consistent with the raw data: the actual recorded value from
experiments is 1.08±0.03 μm.
Statistical Analysis: Budesonide
Table V shows that the particle size distributions and
FPFs have wide ranges. Yet, neither excipients nor drug con-
centrations of the formulation have a significant effect on the
particle size distribution of the deposited drug. Only d25 is
affected by the excipient, suggesting that the particle size
distribution is most sensitive to formulation and actuation
conditions in the smallest particle size range. The use of
ML80 lactose and CP excipients results in the most dramatic
shift in the d25 to a higher particle size (compared to SV94
lactose), suggesting relatively less separation of smaller drug
particles. When considering the FPF of CP, which is signifi-
cantly higher than that of the other excipients, one can see that
the shift in the particle size is likely due to an overall increase
in the release of drug, most of which is larger in size. Varying
the drug concentration, on the other hand, does not have a
statistically significant effect on the d25 of budesonide.
Table V confirms that d25, d50, and d75 of budesonide are
all affected. The use of less turbulent (less energetic) actuation
conditions, represented by a lower Re, results in the release of
fewer fine particles and consequently an increase of all three
particle size indicators to higher values. Remarkably, the ac-
tuation conditions did not have statistically significant effects
Table II. Effect of Last Surface of Contact on Total Charge (Sum
Across All Stages and Sum of Absolute Magnitudes Across All
Stages) for 1% Albuterol in ML58 Lactose, 45–75 μm Sieve Fraction
Formulation, 20 mg Actuated from SETA, Shown in Fig. 4. Range Is








Paper (n=1) 559 663
Carageenan capsule 646–714 758–813




Gelatin capsule 829–860 934–941
Average 752±104 853±100
PE polyethylene
Fig. 8. Budesonide (0.5%) in SV425 lactose, 45–75 μm sieve fraction,
and 20 mg actuated from SET A, off different surfaces. The eight
actuations were performed in a rowwith intermittent placebo actuations.
There are minor magnitude differences but the charge deposition pro-
files are largely the same. This supports the hypothesis that the charges
observed are the result of triboelectrification during actuation, when
particles have undergone charge transfer and those charges are exposed
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on the FPF of budesonide, though this is in part the result of
relatively few data points and high data variability for
budesonide formulations. Changing the excipient appears to
be a more reliable way of increasing the FPF than increasing
the pressure drop during DPI actuation. The effects of excip-
ient size fraction on budesonide delivery were not considered
since only 45–75 μm sieve fractions were used for all excipi-
ents. (They were, however, examined for albuterol formula-
tions.) The d50 value observed in the experiments (~2 μm) was
in good agreement with the primary particle size measured by
light scattering.
Statistical Analysis: Albuterol
The same analysis of particle size and FPF effects was
conducted for albuterol; the results are shown in Table V. As
explained in Section 2.2, more experiments in the experimen-
tal design involved albuterol formulations, and excipient par-
ticle size was also varied, hence the additional rows in the
result table and more effects. Varying the excipient has a
significant effect on each of the response variables, the entire
particle size distribution, as well as the FPF. For d25 and FPF,
the observed trends are largely in agreement with those ob-
served for budesonide. Again, some of the most significant
increases in particle size and FPF are observed for CP, indi-
cating more efficient release of drug compared to the other
excipients. Glucose provides another interesting result; the
entire particle size distribution is shifted to higher particle
sizes, while the FPF registers a decrease. This suggests that
separation of fine particulate drug is limited, which supports
prior suggestions that the small particles are most strongly
affected by formulation changes. While the size fraction of
the excipient does have statistically significant and consistent
effects, the effects on the particle size are relatively minor. Use
of the intermediate excipient sieve fraction (75–106 μm) ap-
pears to result in higher FPF in most cases. The concentration
of drug has a significant effect on the FPF, with the 1% drug
concentration resulting in significantly higher FPF than the
0.5% concentration. (The comparison to 0.25% is less signif-
icant, perhaps once more due to the limited number of exper-
iments using 0.25% drug concentration.) This result supports
the active site hypothesis, whereby the drug first adheres to
the most energetic (“active”) sites of the carrier particles and
then (after active site saturation) distributes around the less
energetic sites of the carrier particle, from which it can detach
more easily. In contrast to budesonide, for which particle size
and FPF were barely affected, albuterol formulations are
significantly affected by the fluidization conditions. Using
more turbulent actuation conditions (higher Re) gives reliably
smaller particle size and higher FPF. This result suggests once
more that primarily the separation of small particles is en-
hanced during actuation.
Experimental Design Analysis: Effect of Formulation Factors
on Electrostatic Charging of Drug
Qualitative Analysis
As in the previous case, it is instructive to first look at the
effects on drug charging qualitatively. Figure 10a–f shows the
Table III. Effect of Last Surface of Contact on Total Charge (Sum
Across All Stages and Sum of Absolute Magnitudes Across All
Stages) for 0.5% Budesonide in SV425 Lactose, 45–75 μm Sieve
Fraction Formulation, and 40 mg Actuated from SET A. Range Is
Given, Except in Last Row Which Gives Actuation Average±Stan-
dard Deviation





Paper (n=1) −795 834
Carageenan capsule −1,080 to −1,086 1,125–1,136
PE dish −1,209 to −1,426 1,254–1,447
Paper with Zerostat (n=1) −1,077 1,129
Gelatin capsule −822 to −959 873–1,003
Average −1,057±205 1,100±199
PE polyethylene
Table IV. Effect of Excipient (All 45–75 μm Sieve Cut), Drug Concentration and Fluidization Conditions on the PSD (Using d25, d50, and d75 as
Surrogate Markers), and FPF of Deposited Budesonide. In the Model, Created by SPSS Software, the Default Value Is Given by the Model
Intercept and the Contribution for Each Factor Is Given in Each Column. Thus, for Example, the d25 of Budesonide From a 0.25% Drug in
ML80 Actuated at Re=18,440 Would Be Expected to be 0.96–0.16+0.28+0.00=1.08 μm (Actual Recorded Value from Experiments Is 1.08±
0.03 μm (n=2))
Factor/response d25 (μm) d50 (μm) d75 (μm) FPF
Data average±σ 1.38±0.28 1.99±0.22 2.73±0.31 0.056±0.061
Data range 1.04–2.05 1.75–2.56 3.34–2.39 0.002–0.219
Model intercept 0.96 1.83 2.59 0.093
Excipient Significant (p=0.034) Not significant Not significant Significant (p=0.001)
Lactose, SV94 0 0
Lactose, SV425 +0.19 −0.042
Lactose, ML58 +0.22 −0.056
Lactose, ML80 +0.28 (p=0.028) −0.054
Glucose +0.11 +0.037
Calcium phosphate +0.38 (p=0.005) +0.127 (p=0.001)
Drug concentration Not significant Not significant Not significant Not significant
Fluidization conditions Significant (p=0.000) Significant (p=0.000) Significant (p=0.019) Not significant
Re=18,440 (SETA) 0 0 0
Re= 11,070 (SET C) +0.25 +0.29 +0.55
Re=7,720 (SET D) +0.73 +0.70 +0.89
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effects of varying the excipient on the mass deposition and the
charge deposition of 0.5% albuterol in 40 mg of 45–75 μm
sieve fraction excipient formulations, actuated from SETA (at
high shear conditions). Figure 11a–f shows the same effects for
budesonide formulations. The mass depositions of drug are
shown in yellow diamonds (left axis), and the charge distribu-
tion (right axis) is shown in red squares.
From Fig. 11a–f, it is evident that the FPM and the
deposited charges vary significantly from excipient to excipi-
ent. While the charge deposition is largely positive for albute-
rol drug actuated from milled lactose (subpanels a and b) and
glucose (subpanel e), sieved lactose formulations (subpanels c
and d) and the CP formulation (subpanel f) show bipolar
charging. Clearly, the mass depositions vary, but the overall
shapes of the particle size distributions are similar (as might be
expected, since it is the same drug). Yet, the charge distribu-
tion is unique for each formulation. This clearly shows that the
formulation has a profound effect on the charging behavior of
the drug. Figure 11 makes the same point for formulations
containing budesonide. The conditions are the same as in
Fig. 11, i.e., 0.5% budesonide in a 45–75-μm fraction of the
excipient, 40 mg actuated from SETA. Note that in this case,
the charge is mostly negative, with some bipolar charging
observed for the formulation containing CP. Milled lactose
formulations also show slight positive peaks in the 0.5-μm
range, which, however, are likely due to the deposition of
some residual excipient particles in that size range (actuations
of excipient only are shown in blue triangles). The charge
distributions of the different budesonide formulations are
much more similar to one another, suggesting that the formu-
lation has a smaller impact.
Charging Differences Between Polydisperse Particles
One striking feature observed throughout Fig. 11 is that
different drug particle size fractions show differences in charg-
ing behavior. The charging behavior does not follow the par-
ticle size distribution and cannot be explained by mass
depositions on the given stages. For instance, when delivered
from SV425 lactose (Fig. 11c), albuterol particles smaller than
~0.5 μm charge positive, particles between 0.5 and 1.0 μm
charge negative, whereas particles above 1 μm charge positive
again. Based on the small size of the error bars (showing
standard deviation of n=3 actuations), this charging pattern
is quite reproducible. The effect is not related to the deposi-
tion of fine excipient particles either, which is minimal as
Fig. 9. Effects of concentration and actuation conditions (high-pres-
sure drop SET A) and low-pressure drop (SET C) and very low-
pressure drop (SET D) on the particle size distribution of albuterol
in 45–75 μm ML80 lactose formulations
Table V. Effect of Excipient, Excipient Sieve Fraction, Drug Concentration, and Fluidization Conditions on the PSD (Using d25, d50, and d75 as
Surrogate Markers) and FPF of Deposited Albuterol. In the Model, Created Using SPSS Software, the Default Value Is Given by the Model
Intercept and the Contribution for each Factor Is Given in Each Column
Factor/response d25 (um) d50 (um) d75 (um) FPF
Data average±σ 0.94±0.18 1.47±0.16 2.10±0.25 0.101±0.051
Data range 0.64–1.24 1.29–1.97 1.80–3.12 0.015–0.194
Model intercept 1.05 1.32 1.80 0.193
Excipient Significant (p=0.000) Significant (p=0.000) Significant (p=0.000) Significant (p=0.004)
Lactose, SV94 0 0 0 0
Lactose, SV425 +0.30 +0.29 (p=0.003) −0.08 −0.036
Lactose, ML58 +0.01 +0.03 +0.05 +0.134 (p=0.014)
Lactose, ML80 −0.11 +0.05 +0.10 −0.019
Glucose +0.17 +0.31 (p=0.033) +0.58 (p=0.006) −0.088
Calcium phosphate +0.49 (p=0.054) +0.46 (p=0.001) +0.65 (p=0.001) +0.051
Excipient size fraction Not significant Significant (p=0.015) Significant (p=0.001) Significant (p=0.006)
45–75 μm 0 0 0
75–106 μm −0.02 −0.04 +0.090 (p=0.005)
106–150 μm +0.04 +0.09 +0.025




Fluidization conditions Not significant Significant (p=0.000) Significant (p=0.000) Significant (p=0.015)
Re=18,440 (SET A) 0 0 0
Re=11,070 (SET C) +0.18 (p=0.065) +0.35 (p=0.013) −0.041
Re=7,720 (SET D) +0.46 (p=0.000) +0.57 (p=0.000) −0.109 (p=0.000)
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shown by the blue graphs in the figures. Clearly, different drug
size fractions have different charging properties.
The phenomenon of charging between particles within a
polydisperse mixture of a material having the same chemical
composition (and thus presumably the same effective work
function) has been observed in other natural and industrial
settings (27–29). In polydisperse mixtures with many surface
contacts, it was found that smaller particles typically acquire
an excess of negative charge while the larger particles tend to
charge more positive (28–30). The phenomenon has been
Fig. 10. Effect of formulation excipient on FPM and charge distribution of albuterol. Mass depositions of drug (μg, yellow
diamonds, axis on left), charge distribution of formulation (fC, red rectangles, n=3±σ, axis on right), and excipient charging
(fC, blue triangles, right axis) are shown. Lines were drawn between points for better visibility
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explained using a largely statistical argument in conjunction
with particle dynamic simulations (31); it was postulated that
high energy electrons are initially uniformly distributed and
during a mixing process concentrate on the surface of the
smaller particle fraction, leaving the smaller particles with an
excess of electrons relative to larger particles in the mixture.
However, this explanation does not adequately describe
the DPI system, where the larger drug particles are not
Fig. 11. Effect of formulation excipient on FPM and charge distribution of budesonide. Mass depositions of drug (μg, yellow
diamonds, left axis), charge distribution of formulation (fC, red rectangles, n=3±σ, axis on right), and excipient charging (fC,
blue triangles, right axis) are shown. Lines were drawn between points for better visibility
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necessarily more positively charged. Moreover, in the DPI
formulation, the drug particles are primarily in contact with
the excipient. Both drug and excipient are somewhat disperse
within some defined particle size ranges (in the figures, it is
0.1–8 μm for the drug and ~45–75 μm for the excipient parti-
cles). The bimodal charging phenomena observed in this study
are more complicated and no explanation is offered. However,
given the small drug particle size and the low concentration,
the drug particles cannot be controlled directly. Instead, the
formulation components and variables offer the better oppor-
tunity for drug particle control, so we now turn to the statis-
tical analysis of the contributions of the formulation variables
to drug triboelectrification.
Statistical Analysis: General
As was the case for the particle size and mass deposition
data, the charge distribution data (consisting of charge distri-
bution data for each ELPI stage over time) were consolidated
into a smaller number of descriptive parameters and analyzed
using SPSS. As before, the general linear model multivariate
procedure was applied. The data in the tables, Tables VI
(budesonide) and VII (albuterol), are organized as previously
discussed. The data average is just the simple, non-weighted
average of all measurements of a given response. This is
important to remember because the statistical design is unbal-
anced as more experiments were conducted around a central
set of conditions (e.g., milled lactose excipient) than for the
other formulations and conditions; this explains part of the
variability.
It is clear that for both budesonide and albuterol formu-
lations, the data variability is very large. Some of this variabil-
ity is due to the naturally random element in charging
phenomena. Some of the extreme data points may be due to
experimental error. Nonetheless, to prevent the introduction
of bias into the analysis, no data points were removed from
the analysis. Since the dataset is extensive, the analysis is not
overwhelmed by a few outliers.
Two important response variables were the total charge
and the dominant polarity. However, to understand the
strength of the charging phenomena, it is important to deter-
mine charge effects relative to the quantity of drug that is
delivered. Charge deposition was recorded using the ELPI
and deposition of drug was determined from chemical assay
of the ELPI stages. Having this data, there are a number of
different ways in which the two measures could be correlated.
Several different response factors were evaluated. Each re-
sponse variable correlates charge to quantity of drug in a
different way using a set of assumptions; the response vari-
ables used are normalized for mass or normalized for surface
area. The different response factors are described in detail:
1. Polarity of charge is determined by summing all the
charges recorded for a given deposition across all the
stages and then, depending on the polarity of the
charge, assigned a −1 or a +1. This response variable
is simple and requires no assumptions. However, the
response is nominal (+1 or −1) and thus not scalable.
2. The total of absolute charge (Sum |Q|), given in units
of nanocoulombs, is the sum of absolute values of
charge recorded across the different ELPI stages. This
response does not take into account the quantity of
material delivered. It is nevertheless considered as a
first step, since the charging phenomena could also
turn out to be a property of the actuation process,
relatively independent of mass.
3. Absolute charge per mass (Sum |Q|/m), given in units
of microcoulombs per gram, is determined by summing
all the absolute values of the charges recorded across
all the ELPI stages and then dividing by the total mass
that was recovered from all the stages.
4. Charges/area, given in elementary charges (1e−=1.6×
10−19 C) per square micrometer, is the sum of charges
divided by the surface area of the deposited drug
particles. This response variable assumes that
deposited drug on each stage consists of spheres with
particle size exactly at the midpoint between the cutoff
sizes of the corresponding and the previous stage. This
is an oversimplification as the drug particles are
prismatic in shape and have a range of sizes. The
assumption of sphericity underestimates the true
surface area; thus, the true charges/area measures are
likely to be smaller. But this simplification should not
affect the outcome of the analysis, since it applies the
simplifying assumption to all size fractions for each
drug.
5. Average charges per particle (stages 7–10) is the esti-
mated per-particle charge (in elementary charges) for
drug deposited on stages 7–10, which includes particles
from 0.655 μm (cutoff size of stage 7) to 4.09 μm
(cutoff size of stage 11). These four stages account
for most of total drug deposited inside the ELPI (in
most cases, over 85%). Due to the high material de-
positions on these stages, there is a high level of con-
fidence associated with the mass determinations. Using
the material densities (1.3 g/cm3 for albuterol, 1.25 g/
cm3 for budesonide) and basic geometric assumptions
(particles are uniform spheres of average size for a
given stage), the mass depositions on each stage are
converted into numbers of particles. The charge
collected on each stage is given in elementary
charges, which are divided by the number of
particles. This measure is an oversimplification,
though the approach is uniform and does not
introduce any bias into the statistical analysis. While
the charge density (charge per area, in (4)) is
physically the most important response, the “per
particle” charge is probably the most clinically
relevant measure. After all, the total charge on a
particle determines its trajectory and deposition.
The three normalized response variables (3–5) follow the
same basic trends in most cases and are not discussed individ-
ually in detail.
Statistical Analysis: Budesonide
Table VII summarizes the effects of formulation variables
on the charging behavior of budesonide particles. The drug
consistently charged negatively and the polarity was not af-
fected by the type of excipient. Every other response was
significantly affected by the choice of excipient, the
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concentration of the drug, the fluidization conditions, and
even the dose. The effects of drug concentration, fluidization
conditions, and dose on the absolute magnitude of the charge
are expected and are related in part to the larger drug deposi-
tions. However, as the mass normalized charge measures show,
the effects are smaller than might be expected based on mass
depositions alone. On a per particle basis, the milled lactose
batches result in the strongest (negative) charging of the drug
particles, while glucose andCP result in least charge per particle.
The lower drug concentrations of 0.25% and 0.50% produce
higher particle charges than the higher 1% drug concentration
formulations. This may be the result of stronger contact charging
due to closer drug–excipient contact in lower concentration drug
blends. (The smallest charge contribution of the 0.25% formu-
lation does not support this conclusion, though the effect is
variable and lacks statistical significance.) The charge contribu-
tion associated with the drug concentration is minor compared
with the effects of excipient or fluidization conditions. Fluidiza-
tion conditions significantly affect the charge. The parameter
estimates for this effect are counterintuitive: the analysis reveals
higher per particle charges for the less intense fluidization con-
ditions (Re=11,070 and 7,720) than the more turbulent condi-
tions (Re=18,440). A possible explanation is that when fewer
particles are dispersed, the likelihood of contact and charge
backflow in transit is smaller, i.e., it is less likely that opposite
charges cancel each other. This explanation is supported by the
fact that the smaller actuation dose also gives rise to more highly
charged particles. Additionally, lower Re fluidization conditions
result in the release of fewer fine particles shifting the
distribution to larger particles, which have larger surface areas
and can accommodate more charges.
Statistical Analysis: Albuterol
The effects that formulation variables have on the charging
of albuterol are summarized in Table VII. With a larger number
of trials conducted, the dataset around albuterol is richer (it
includes an analysis of excipient size fractions as well), and as a
result, there is more confidence in the individual parameter esti-
mates. The excipient clearly impacts the polarity of charge.
Whereas budesonide always charged negatively, albuterol
charged either positive or negative, depending on the excipient
in the formulation. Formulated with SV94 lactose, albuterol par-
ticles were predominantly negatively charged. Formulated with
the other sieved lactose batch, SV425, albuterol particles were
either negatively or positively charged, whereas in combination
with glucose and CP, albuterol primarily charged positively. It can
be deduced that albuterol has a pseudo-work function that is
somewhere in between that of sieved lactose and glucose. No
other variables affected charge polarity significantly. However, all
formulation variables, i.e., excipient, excipient size fraction, drug
concentration, and fluidization conditions, had effects on absolute
and relative chargemagnitudes. In the case of drug concentration,
fluidization conditions, and dose, larger charges were associated
with increased deposition of drug, that is higher concentration,
more turbulent charging, and larger dose resulted in higher
charge depositions. However, a look at the normalized responses
shows that increased mass delivery does not fully account for the
Table VI. Formulation Variables Contributing to the Charging of Budesonide. Effect of Excipient, Excipient Size Fraction, Drug Concentra-
tion, Fluidization Conditions, and Dose on the Charging Behavior of Fine Particulate Albuterol. In the Model, Created Using SPSS Software,
the Default Value Is Given by the Model Intercept and the Contribution for Each Factor Is Given in Each Column. Also Shown Is the










per particle (stages 7–10)
Data average±σ −1±0 0.73±0.27 64.8±76.4 1,333±2,003 6,112±7,930
Data range −1 0.35–1.31 6.9–304.1 70–8,054 363–32,312
Model intercept −1 1.20 −8.8 −294 −296







Lactose, SV94 0 0 0 0
Lactose, SV425 +0.11 +23.3 (p=0.006) +379 (p=0.005) +1,640 (p=0.039)
Lactose, ML58 +0.00 +40.7 (p=0.001) +759 (p=0.000) +3,210 (p=0.005)
Lactose, ML80 +0.11 +38.6 (p=0.001) +762 (p=0.000) +2,690 (p=0.011)
Glucose −0.31 (p=0.020) −9.8 −104 −971
Calcium phosphate +0.24 (p=0.047) −7.6 −76 −874







1.00% 0 0 0 0
0.50% −0.43 (p=0.010) +25.4 (p=0.008) +487 (p=0.003) +1,690 (p=0.056)
0.25% −0.90 (p=0.000) +0.2 −156 +773







Re=18,440 (SET A) 0 0 0 0
Re=11,070 (SET C) −0.37 (p=0.010) +10.2 +258 (p=0.022) +2,040 (p=0.018)
Re=7,720 (SET D) −0.52 (p=0.004) +248.8 (p=0.000) +7,100 (p=0.000) +2,820 (p=0.000)







40 0 0 0 0
20 −0.33 (p=0.028) +2.0 +38.6 +158
1393Properties of Model Dry Powder
additional charge. As seen before with budesonide, smaller drug
concentrations and less turbulent actuation conditions result in
higher per particle charges. The positive effect of the smaller drug
concentration on charge supports the active site hypothesis. The
lower Re actuation conditions also result in higher per particle
charges, though the effects are variable and the individual param-
eter contributions lack statistical significance. This result is in
agreement with the results for budesonide. As stated previously,
one explanation for this is the shift towards larger particle sizes,
which can accommodate larger charges. Furthermore, fewer dis-
persed particles create fewer opportunities for charge neutraliza-
tion or backflow. Excipient particle size also contributes to
particle charging. The charge of the delivered drug decreases as
the excipient particles increase in size. While the overall contri-
bution of the effect is modest, the effect is nonetheless consistent
with a surface area effect; as the carrier particles become larger,
their specific surface area decreases and the drug particles reach a
higher degree of surface saturation on the carrier particle surface.
The drug particles become less charged because there is less
surface area available with which to exchange electrons. This
explanation may be seen as an extension of the active site hy-
pothesis, provided the highly energetic surface sites are also more
prone to electron exchange.
It is noteworthy that CP and glucose result in the least
charged budesonide particles but give rise to the most highly
charged albuterol particles. These observations seem at odds
but are actually consistent with each other when the polarities
of the charges are considered: in both instances, CP and
glucose result in the most positive drug charges. This allows
CP and glucose to be placed at the very top of the triboelectric
series. Construction of a triboelectric series for the materials
and the ramifications thereof are discussed in the next section.
Per Particle Charge Levels
One of the primary aims of this research was to determine
the role electrostatic charging plays in DPI particle interac-
tions. A number of simulation (32) and in vivo (33) studies
have suggested that micron-size particles need to have charges
in the 100 s of elementary charges range to be affected in their
trajectory and their deposition in the respiratory tract. Using
Faraday cage data and some basic geometric assumptions,
Byron et al. (34) estimated that DPI particles could have
charges in the 200e per particle range.
The results of this study indicate triboelectric charging in
the DPI can give rise to significant charging with charge levels
that are much higher than previously estimated. Surveying the
data range for budesonide formulations (Table VII) and albu-
terol formulations (Table VII), the data indicate per particle
charge levels of 542±381 and 6,112±7,930 elementary charges
Table VII. Formulation Variables Contributing to the Charging of Albuterol. Effect of Excipient, Excipient Size Fraction, Drug Concentration,
Fluidization Conditions, and Dose on the Charging Behavior of Fine Particulate Albuterol. In the Model, Created Using SPSS Software, the
Default Value Is Given by the Model Intercept and the Contribution for Each Factor Is Given in Each Column. Also Shown Is the Significance
Level of the Formulation Variable (from ANOVA), as well as the Level of Significance for Each Individual Variable Level (Where p≤0.05)
Factor/response
1. Polarity of






per particle (stages 7–10)
Data average±σ 0.74±0.68 0.77±0.52 6.3±12.9 142±80 542±381
Data range −1–+1 0.89–2.12 1.5–30.5 16.5–395.3 43–2,092










Lactose, SV94 −1 0 0 0 0
Lactose, SV425 ± 0 +0.26 +10.6 (p=0.008) +127.2 (p=0.002) +138
Lactose, ML58 +1 (p=0.000) +2.10 (p=0.009) +16.2 (p=0.026) +207.3 (p=0.005) +842 (p=0.01)
Lactose, ML80 +1 (p=0.000) +0.63 +13.2 (p=0.002) +117.1 (p=0.002) +597 (p=0.03)
Glucose +1 (p=0.000) −0.08 +16.4 (p−0.016) +191.1 (p=0.005) +1,236 (p=0.000)










45–75 μm +0.34 +9.6 (p=0.018) +96.4 (p=0.013) +216
75–106 μm 0 0 0 0
106–150 μm −0.91 (p=0.028) −5.2 −47.2 −135







1.00% 0 0 0 0
0.50% −0.61 +13.8 (p=0.014) +86.9 +245








Re=18,440 (SETA) 0 0 0
Re=11,070 (SET C) −0.79 −3.7 +267
Re=7,720 (SET D) −0.78 (p=0.030) +110.5 (p=0.003) +65
Dose (mg) Not significant Significant
(p=0.004)
Significant Not significant Not significant
40 0 0
20 −0.50 +2.59
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per particle (unbalanced, non-weighted means of entire dataset
±standard deviation) on albuterol and budesonide particles in
the 0.655-μm (stage 7) to 4.09-μm (stage 10) range, respectively.
Particles in this size range account for the bulk of the drug
delivered to the lungs. Figure 12 shows the entire charge distri-
bution (absolute magnitude) for two representative formula-
tions, 0.5% budesonide in ML80 lactose (45–75 μm sieve
fraction) and 0.5% albuterol in ML58 lactose, as well as the
upper and lower charge limits. The lower limit is the Boltzmann
equilibrium charge distribution, which is the charge level expect-
ed for naturally occurring aerosols. The average number of






where dp is the particle diameter given in micrometer. Equa-
tion 1 is an empirical relationship that is accurate to within
±5% for particles greater than 0.2 μm (26). The Boltzmann
distribution predicts charges of less than ±5 (elementary
charges) for most particles with dp<5 μm.
While the Boltzmann charge distribution gives the lower
limit of charge for an aerosol, the maximum number of nega-





where dp is the particle diameter, EL is the surface field strength
required for spontaneous electron emission (9.0×108 V/m), KE
is the Coulomb’s law constant, and e is the charge of an electron,
1.6×10−19 C (26). Above this upper limit, spontaneous emission
of electrons from a surface is expected. The graphs indicate very
high charges, well into the 1,000 s and even 10,000 s of
elementary charges per particle range. These charges (not the
highest charge levels recorded in these experiments) far exceed
the Boltzmann equilibrium charge distribution and clearly
implicate an active charging process, specifically contact
charging in the formulation. As indicated in Table VII, the
formulation variables have significant effects on the charge
distribution and can produce much higher particle charge levels.
SUMMARYAND CONCLUSION
The ELPI offers significant advantages for studying elec-
trostatic interaction between the particles in DPI formula-
tions. The most significant advantage, which sets the
instrument apart from other scientific instruments or experi-
mental apparatuses, is its ability to measure particle size and
charge distributions simultaneously for particles in the single-
micron range, the size range required for respiratory drug
delivery. An experimental apparatus was developed that
allowed different DPI formulations to be tested at the com-
monly used 60 L/min flow rate and deposition to be measured
within the ELPI. An experimental framework was devised to
test which formulation factors contribute to triboelectric
charging in DPI formulations. The framework included rough-
ly 100 experiments (including replicates and auxiliary experi-
ments), of which a number of replicates had to be excluded
due to storage effects. While out of scope of this discussion,
the storage effects (highlighted in Fig. 12) are significant and
warrant further investigation.
The remaining experiments offer an extensive dataset of
charge and mass deposition data that give insight into which
formulation factors contribute to triboelectric charging in the
DPI. The choice of excipient is clearly important and most
profoundly affects the charge characteristics of the deposited
drug. Batch-to-batch variability in the behavior of the four
lactose batches was clearly indicated; it is clear that some
excipients behave differently when combined with albuterol
or budesonide, which shows the difficulty in determining cer-
tain effects a priori.
The particle size of the excipient also appears to have an
effect on the charge profile of deposited drug, with smaller
particles (with increased surface area) giving rise to stronger
charging interactions.
The concentration of drug in the DPI formulation was
also shown to affect the particle charge; lowering the drug
concentration results in lower fine particle fractions with
more highly charged drug particles, a result that adds weight
Fig. 12. Charge distribution (average particle charge) for drug depos-
ited in ELPI. Shown are 0.5% budesonide in ML80 lactose (45–
75 μm) (blue diamonds) and 0.5% albuterol in ML58 lactose (45–
75 μm) (yellow diamonds), both actuated from SETA (high Re). For
comparison, the graph shows the charge limit expected for the parti-
cles (green triangles) and the Boltzmann charge distribution (red
squares). In both cases, over 80% of the deposited particles carry
>100 charges per particle
Table VIII. Using Formulation Techniques to Affect Drug Charging
To minimize drug particle charge To maximize drug particle charge
• Increase drug coverage (drug concentration) of excipient particle • Reduce drug concentration
• Increase excipient particle size • Decrease excipient particle size
• Use excipients with similar effective work function
(i.e., close position in triboelectric series)
• Use excipients with different effective work
function (i.e., further removed from drug in triboelectric series)
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to the often cited “active site hypothesis”: due to lower
surface coverage, drug particles are concentrated around
more energetic carrier particle surface sites where forces
are stronger and electron exchange may be more extensive;
as a result, fewer particles separate from the carrier.
The actuation conditions also have a strong effect on the
particle size and charge distribution of drug. Contrary to expec-
tations, however, more turbulent conditions result in somewhat
lower per particle charge levels. This result is consistent with the
idea that contact charging is the cause of the particle charge and
that fluidizationmerely affects the particle separation process.A
lower delivered dose also slightly raises the particle charge level.
An explanation for these results is that a smaller amount of
dispersed drug decreases the chance of opposite charges cancel-
ing each other during transit or deposition.
While the study provided statistically strong evidence for
profound effects of some formulation variables, the study
design also had some weaknesses. The inherent variability of
the charging phenomena was underestimated; as a result,
some of the marginal conditions that were written into the
design to test response surface curvature lacked sufficient data
and, thus, statistical power to give conclusive results: the very
low drug concentration of 0.25% and the very low Re actua-
tion conditions have too few response points and too much
variability to provide trends.
The results indicate that particle charging in DPI formu-
lations is highly significant. Charging is at least one order of
magnitude higher than had previously been estimated, and
greater particle charges are generated during DPI actuation
than in many other industrial or laboratory processes. The
particle charge levels are indicative of the active contact charg-
ing process and provide a scientific basis for the problems with
electrostatic charging which have been observed in the clinical
use of respiratory delivery devices, MDIs and DPIs.
The charge levels are high enough to have clinical conse-
quences, either due to change in trajectory, adhesion to de-
vice, or modified in vivo deposition patterns. The study
suggests electrostatic interactions should be studied during
DPI formulation development. Failure to consider the process
is, at best, a lost opportunity to moderate a phenomenon that
can be affected through formulation considerations.
Table VIII summarizes how charging can be affected.
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